Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
HEPATITIS | B REP 2139 | Clinical Trials | Replicor
Detection of DHBsAg in liver at the end of follow-up in the REP 2139 ...
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir ...
New Hope for Hepatitis B & D: Rep 2139 Compassionate Access Program ...
Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell ...
(PDF) Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered ...
(PDF) Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir ...
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for ...
CHARACTERIZATION OF THE DIRECT ANTIVIRAL EFFECT OF REP 2139 IN 2D AND ...
Chemical structures of REP 2055 (A) and REP 2139 (B). | Download ...
(PDF) Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act ...
REP 2139: Antiviral Mechanisms and Applications in Achieving Functional ...
Compassionate use of subcutaneously administered REP 2139-Mg in ...
Compassionate use of subcutaneous REP 2139-Mg in cirrhotic HBV / HDV ...
Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or ...
On-treatment antiviral response in the nine REP 2139-Ca patients in the ...
Research review of new hepatitis B drug REP 2139, 401, functional ...
Safety and efficacy of REP 2139-Mg in patients with HDV-related ...
Updated follow-up analysis in the REP 401 protocol: treatment HBeAg ...
(PDF) Updated follow-up analysis in the REP 401 protocol: Treatment ...
Fast Response to REP 2139-Mg in 3 With HDV/HBV and Decompensated Cirrhosis
Safety and efficacy of REP 2139-Mg in hepatitis D patients with ...
Summary of antiviral effect of REP 2139-Ca and immunotherapy during ...
Safety and efficacy of REP 2139-Mg in hepatitis D patients: reporting ...
慢乙肝治疗新动向：REP 2139-Ca - 知乎
Hepatitis Delta (HDV) Archives - Hepatitis B Foundation
Functional remission of HBeAg negative chronic HBV infection after ...
乙肝在研新药REP 2139联合聚乙二醇干扰素α治疗HBV/HDV共感染患者的功能性治愈率良好 - 知乎
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus ...
(PDF) Variants of hepatitis B virus surface antigen observed during ...
After the hepatitis B 2023 sub-hepatitis meeting, Replicor introduced ...
B型肝炎ウイルス (HBV) 表面抗原を発現するCRISPR/Cas9改変細胞株におけるREP 2139の汎ゲノム抗ウイルス効果 ...
B肝在研新藥REP 2139，抑制HBsAg分泌，作用機理繼續得到證明 - 每日頭條
重磅：有望功能治癒B肝新藥REP2139∕2165即將進行3期臨床試驗！ - 每日頭條
乙肝在研新药REP 2139，抑制HBsAg分泌，作用机理继续得到证明|DNA|相互作用|研究人员|核酸|酸性_新浪新闻
【期刊导读】乙肝在研新药REP 2139联合聚乙二醇干扰素α治疗HBV/HDV共感染患者的功能性治愈率良好|治愈率|干扰素|乙肝|患者 ...
慢性乙肝在研新药盘点 - 药时代DrugTimes
B肝在研新藥REP2139，HepG2細胞，阻斷表面抗原分泌 - 每日頭條
REP-2139(REP-2139) - 药物靶点：HBsAg_专利_临床_研发
Establishment of High Rates of Functional Control and Reversal of ...
Mechanism of action of hepatitis B virus S antigen transport-inhibiting ...
B肝在研新藥REP 2139，B肝合併丁肝模型，亞病毒顆粒更新迅速 - 每日頭條
乙肝/丁肝在研新药REP2139，挽救BLV失败，在HDV取得积极进展|防疫|疫情|受试者|科学|药物_新浪新闻
乙肝/丁肝在研新药REP 2139，通过SC，挽救BLV失败及反弹数据|受试者|丁肝|乙肝_新浪新闻
Challenges and Solutions in pgRNA Measurement: Toward Improved ...
Replicor公布REP 2139进度，乙肝在研新药，支持多基因型感染者|基因型|乙肝|抗原_新浪新闻
VIR-3434 Phase 1-study made by Vir Biotechnology - Trials, studies ...
2023全球肝炎峰会：核酸聚合物REP 2139慢乙肝REP 401研究5年随访结果公布！_HBsAg_治疗_患者
IDCM — Infectious Diseases and Clinical Microbiology
30288-1/asset/417ff852-5b44-499c-80b6-b8e301de4c78/main.assets/gr2_lrg.jpg)
30288-1/asset/61a9b73e-15e5-44c4-a83a-4c51c573bc2d/main.assets/gr3_lrg.jpg)
